Recent News

• 01.12.2026 - Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications
• 12.03.2025 - Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology
• 11.13.2025 - Relmada Therapeutics Reports Third Quarter 2025 Financial Results and Provides Key Clinical, Regulatory, and Corporate Updates
• 11.13.2025 - Relmada Therapeutics Reports Third Quarter 2025 Financial Results and Provides Key Clinical, Regulatory, and Corporate Updates
• 11.07.2025 - Relmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025

Recent Filings

• 12.16.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.16.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.16.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.16.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.16.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.16.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.16.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.15.2025 - 8-K Current report
• 11.14.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 11.13.2025 - 8-K Current report